146 related articles for article (PubMed ID: 37759704)
1. The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson's Disease.
Albus A; Kronimus Y; Burg-Roderfeld M; van der Wurp H; Willbold D; Ziehm T; Dodel R; Ross JA
Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759704
[TBL] [Abstract][Full Text] [Related]
2. Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays.
Heinzel S; Gold M; Deuschle C; Bernhard F; Maetzler W; Berg D; Dodel R
PLoS One; 2014; 9(12):e114566. PubMed ID: 25470145
[TBL] [Abstract][Full Text] [Related]
3. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers.
Majbour NK; Aasly JO; Hustad E; Thomas MA; Vaikath NN; Elkum N; van de Berg WDJ; Tokuda T; Mollenhauer B; Berendse HW; El-Agnaf OMA
Transl Neurodegener; 2020 May; 9(1):15. PubMed ID: 32375873
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease.
Folke J; Rydbirk R; Løkkegaard A; Hejl AM; Winge K; Starhof C; Salvesen L; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T
Parkinsonism Relat Disord; 2021 Jun; 87():98-104. PubMed ID: 34020303
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
[TBL] [Abstract][Full Text] [Related]
6.
Garrido A; Fairfoul G; Tolosa ES; Martí MJ; Green A;
Ann Clin Transl Neurol; 2019 Jun; 6(6):1024-1032. PubMed ID: 31211166
[TBL] [Abstract][Full Text] [Related]
7. Naturally occurring autoantibodies against α-synuclein rescues memory and motor deficits and attenuates α-synuclein pathology in mouse model of Parkinson's disease.
Huang YR; Xie XX; Ji M; Yu XL; Zhu J; Zhang LX; Liu XG; Wei C; Li G; Liu RT
Neurobiol Dis; 2019 Apr; 124():202-217. PubMed ID: 30481547
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
[TBL] [Abstract][Full Text] [Related]
9. Effect of naturally occurring α-synuclein-antibodies on toxic α-synuclein-fragments.
Rabenstein M; Besong Agbo D; Wolf E; Dams J; Nicolai M; Roeder A; Bacher M; Dodel RC; Noelker C
Neurosci Lett; 2019 Jun; 704():181-188. PubMed ID: 30954607
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early-Onset Parkinson's Disease.
Chen Y; Gu X; Ou R; Zhang L; Hou Y; Liu K; Cao B; Wei Q; Li C; Song W; Zhao B; Wu Y; Cheng J; Shang H
Mov Disord; 2020 Nov; 35(11):2046-2055. PubMed ID: 32677286
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
[TBL] [Abstract][Full Text] [Related]
12. Lipid pathway dysfunction is prevalent in patients with Parkinson's disease.
Galper J; Dean NJ; Pickford R; Lewis SJG; Halliday GM; Kim WS; Dzamko N
Brain; 2022 Oct; 145(10):3472-3487. PubMed ID: 35551349
[TBL] [Abstract][Full Text] [Related]
13. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.
Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL
Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134
[TBL] [Abstract][Full Text] [Related]
14. Distinct Autoimmune Anti-α-Synuclein Antibody Patterns in Multiple System Atrophy and Parkinson's Disease.
Folke J; Rydbirk R; Løkkegaard A; Salvesen L; Hejl AM; Starhof C; Bech S; Winge K; Christensen S; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T
Front Immunol; 2019; 10():2253. PubMed ID: 31616427
[TBL] [Abstract][Full Text] [Related]
15. Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease.
Besong-Agbo D; Wolf E; Jessen F; Oechsner M; Hametner E; Poewe W; Reindl M; Oertel WH; Noelker C; Bacher M; Dodel R
Neurology; 2013 Jan; 80(2):169-75. PubMed ID: 23255825
[TBL] [Abstract][Full Text] [Related]
16. The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo.
Cresto N; Gardier C; Gaillard MC; Gubinelli F; Roost P; Molina D; Josephine C; Dufour N; Auregan G; Guillermier M; Bernier S; Jan C; Gipchtein P; Hantraye P; Chartier-Harlin MC; Bonvento G; Van Camp N; Taymans JM; Cambon K; Liot G; Bemelmans AP; Brouillet E
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201785
[TBL] [Abstract][Full Text] [Related]
17. Brain and Cerebrospinal Fluid α-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
Garrido A; Fairfoul G; Tolosa E; Marti MJ; Ezquerra M; Green AJE
Mov Disord; 2023 Feb; 38(2):333-338. PubMed ID: 36471633
[TBL] [Abstract][Full Text] [Related]
18. Pathological Functions of LRRK2 in Parkinson's Disease.
Jeong GR; Lee BD
Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
[TBL] [Abstract][Full Text] [Related]
20. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]